| Patient | Audre Lorde |
|---|---|
| Date of birth | 1934-02-18 |
| Identifiers | MRN HR-ML016-SYN-TD; SSN (made up) 000-16-2937 |
| Document date | 1979-06-29 |
| Author | Naomi Fairweather, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month survivorship visit on tamoxifen. [S]
Ms. Lorde returns three months after the consultation visit. She has taken tamoxifen daily for eight months. The cooling measures and paced breathing have helped: she now has one or two mild hot flashes a day and is rarely woken at night, so she has not needed venlafaxine. Her periods are regular and lighter, with no bleeding between them. She has had no leg swelling, breathlessness, bone pain, cough, or new lumps, and no swelling or heaviness of the right arm. She walks about 30 minutes most days and has been writing and giving readings. The genetic counseling clinic has offered its first appointment in early October. [S]
| Element | Detail |
|---|---|
| Interval change | Hot flashes fewer with non-drug measures |
| Tamoxifen | Eight months, taken daily |
| Recurrence symptoms | None |
| Function | Walking about 30 minutes most days; writing and giving readings |
| Genetic counseling | First available appointment in early October |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight stable; energy good |
| Endocrine | Positive | One or two mild hot flashes a day |
| Genitourinary | Negative | No abnormal vaginal bleeding |
| Cardiovascular | Negative | No leg swelling or chest pain |
| Musculoskeletal | Negative | No bone or joint pain |
| Psychiatric | Negative | Mood good; PHQ-9 score 3 and GAD-7 score 2 |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Tamoxifen 20 mg oral tablet, one tablet by mouth once daily, planned for at least five years | One tablet once daily | Oral route | 1978-10-27 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1979-06-29 | Body height | 168 | cm | S |
| 1979-06-29 | Body weight | 71.6 | kg | S |
| 1979-06-29 | Body mass index (BMI) [Ratio] | 25.4 | kg/m2 | S |
| 1979-06-29 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1979-06-29 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1979-06-29 | Heart rate | 70 | /min | S |
| 1979-06-29 | Respiratory rate | 14 | /min | S |
| 1979-06-29 | Body temperature | 36.7 | Cel | S |
| 1979-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1979-06-29 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 1979-06-29 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 2 | {score} | S |
Vital signs recorded on 1979-06-29; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Breasts and chest wall | Right chest wall flat, scar supple, no nodules; left breast without masses |
| Lymph nodes | No axillary, supraclavicular, or cervical nodes |
| Extremities | Arm circumference 29.0 cm on each side; calves soft and non-tender |
| Abdomen | Soft; liver not enlarged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Invasive ductal carcinoma of the upper outer quadrant of the right breast, stage IA (pT1c pN0(sn) M0), grade 2, estrogen and progesterone receptor positive, HER2 negative, recurrence score 14; treated by right total mastectomy with sentinel node biopsy and on adjuvant tamoxifen; synthetic modern counterpart of the documented 1931 breast cancer and mastectomy | active | confirmed | C50.411 | S — Synthetic tumor details and treatment; the diagnosis and the mastectomy are documented (D), but no tumor details from her lifetime are used. |
| Estrogen receptor positive status of the breast cancer (ER 90 percent, PR 60 percent) | active | confirmed | Z17.0 | S — Synthetic receptor result; no receptor status from her lifetime is known. |
| Absence of the right breast after mastectomy with flat closure; she chose not to have reconstruction and not to wear an external prosthesis | active | confirmed | Z90.11 | S — Synthetic coding of the documented mastectomy; the decision about a prosthesis echoes her documented choice and is respected as her own. |
| Long-term use of tamoxifen as adjuvant endocrine therapy | active | confirmed | Z79.810 | S — Synthetic treatment status. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Cancer-related history and physical examination | Every 3 to 6 months for the first 3 years | Completed today | No symptoms or signs of recurrence |
| Medication safety | Tamoxifen adherence and side effects | Every visit | Completed today | Taken daily for eight months |
| Survey | Vasomotor symptom assessment | Periodically on endocrine therapy | Completed today | One or two mild hot flashes a day; no medicine needed |
| Examination | Abnormal vaginal bleeding inquiry on tamoxifen | Every visit | Completed today | Regular, lighter periods; no intermenstrual bleeding |
| Examination | Venous thromboembolism symptom inquiry on tamoxifen | Every visit | Completed today | No leg swelling, calf pain, or breathlessness |
| Examination | Lymphedema assessment and risk-reduction counseling | Every visit | Completed today | No swelling; arm circumferences equal |
| Survey | Distress, depression, and anxiety screen (PHQ-9 and GAD-7) | At periodic intervals | Completed today | PHQ-9 3 and GAD-7 2, minimal; down from 4 and 3 at intake |
| Survey | Fatigue, cognitive concerns, and sexual or vaginal symptoms | At each visit or periodically | Completed today | None reported |
| Laboratory | Routine blood counts, chemistry, liver tests, and tumor markers (CEA, CA 15-3, CA 27.29) | Not recommended in asymptomatic stage I to III survivors | Not indicated | No symptoms to prompt testing; none ordered |
| Imaging | CT, bone scan, PET, or other imaging for distant spread | Not recommended in asymptomatic survivors | Not indicated | No symptoms; not ordered |
| Imaging | Diagnostic mammogram of the left breast | Yearly after mastectomy | Due | Booked for September |
| Imaging | Bone density (DXA) | Every 2 years on an aromatase inhibitor, on tamoxifen with ovarian suppression, or after chemotherapy-induced menopause | Not indicated | Premenopausal on tamoxifen alone; bone health by diet, vitamin D, and weight-bearing exercise |
| Referral | Genetic counseling | Once | Referred | Still on the waiting list three months after the request; first appointment early October. The clinic coordinator was asked to offer any earlier cancellation. No result is needed for her current care |
| Self-management | Healthy lifestyle counseling | Every visit | Completed today | Walking about 200 minutes a week; strength exercise twice a week started |
Goal progress:
Guideline basis: American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026)
Follow-up: Left mammogram in September, then a survivorship visit. Genetic counseling in October. Next scheduled visit 1979-09-28: survivorship visit one year after diagnosis, after the yearly mammogram of the left breast. [S]